For the month of May 2022

Date of Report (Date of Earliest Event Reported)


Commission File Number: 001-889109


Belite Bio, Inc

(Exact name of registrant as specified in its charter)


Not Applicable

(Translation of Registrant´s name into English)


5820 Oberlin Drive, Suite 101,

San Diego, CA 92121


(Address of principal executive office)


Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x        Form 40-F ¨


Indicate by check mark if the Registrant is submitting this Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes ¨        No x


Indicate by check mark if the Registrant is submitting this Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes ¨       No x


Indicate by check mark whether the registrant by furnishing the information contained in this Form 6-K is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934

Yes ¨          No x






Exhibit Index


Exhibit 99.1 — Press Release







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


  Belite Bio, Inc
  By: /s/ Yu-Hsin Lin
  Name: Yu-Hsin Lin
  Title: Chief Executive Officer and Chairman


Date: May 12, 2022




Exhibit 99.1


Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public Offering


SAN DIEGO, Calif., May 12, 2022--(GLOBE NEWSWIRE)—Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases such as dry AMD and Stargardt disease, and metabolic diseases, today announced that the underwriters of its previously announced initial public offering (the “IPO”) have exercised in part their over-allotment option to purchase an additional 772,091 American Depositary Shares (the “ADS”) of the Company at the IPO price of $6.00 per ADS. Each ADS represents one ordinary share of Belite.


After giving effect to the partial exercise of the over-allotment option, Belite has issued and sold a total of 6,772,091 ADSs in the IPO, for total gross proceeds of approximately $40.63 million, before deducting underwriting discounts and commissions and offering expenses paid by Belite. Belite expects to use the net proceeds from the offering to fund the Phase 3 clinical trial of LBS-008 for STGD1, further clinical development of LBS-008 for dry AMD, working capital and other general corporate purposes.


The Benchmark Company, LLC acted as sole book-running manager for the offering.


A registration statement related to the offering has been filed with the U.S. Securities and Exchange Commission (the “SEC”) and was declared effective on April 28, 2022. The offering was made only by means of a prospectus forming a part of the registration statement. Electronic copies of the final prospectus relating to the offering may be obtained by visiting the SEC's website located at http://www.sec.gov or by contacting The Benchmark Company, LLC, Attention: Prospectus Department, 150 E. 58th Street, 17th floor, New York, NY 10155, by email at prospectus@benchmarkcompany.com, or by telephone at (212) 312-6700.


This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.


About Belite Bio


Belite Bio is a San Diego based clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration (commonly known as dry AMD) and autosomal recessive Stargardt disease, and metabolic diseases. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com.


Important Cautions Regarding Forward Looking Statements


This press release contains certain "forward-looking statements" within the meaning of federal securities laws. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about Belite’s beliefs and expectations. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in Belite’s filings with the U.S. Securities and Exchange Commission at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.



Media and Investor Relations Contact:


Jennifer Wu /ir@belitebio.com


Tim McCarthy /tim@lifesciadvisors.com